Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD)
- DOI
- 10.4103/ijem.ijem_848_25
- Published
- 2026-07
- Container
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.4103/ijem.ijem_848_25,
title = {Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD)},
author = {Bijay K. Das and Sambit Das and Dayanidhi Meher and Arun K. Choudhury and Sourav Padhee and Sandeep K. Sahu and Devadarshini Sahoo and Binod Prusty and Vishal Agarwal},
year = {2026},
journal = {Indian Journal of Endocrinology and Metabolism},
doi = {10.4103/ijem.ijem_848_25},
url = {https://doi.org/10.4103/ijem.ijem_848_25}
}RIS
TY - JOUR TI - Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD) AU - Bijay K. Das AU - Sambit Das AU - Dayanidhi Meher AU - Arun K. Choudhury AU - Sourav Padhee AU - Sandeep K. Sahu AU - Devadarshini Sahoo AU - Binod Prusty AU - Vishal Agarwal PY - 2026 JO - Indian Journal of Endocrinology and Metabolism DO - 10.4103/ijem.ijem_848_25 UR - https://doi.org/10.4103/ijem.ijem_848_25 ER -
APA
Das, B. K., Das, S., Meher, D., Choudhury, A. K., Padhee, S., Sahu, S. K., Sahoo, D., Prusty, B., & Agarwal, V. (2026). Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD). Indian Journal of Endocrinology and Metabolism. https://doi.org/10.4103/ijem.ijem_848_25
Source records
- crossref · retrieved 2026-09-25T20:22:33.231Z